Delivery Order SPE2DB22D1106-SPE2DB25FDXE3

Award Date 2/3/25
Potential Completion Date 2/25/25
Potential Value $30K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,490.29 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML medical products. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
This federal contract award, valued at $19,432.70, was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. The award is a Delivery Order under an existing Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,391.75 Firm Fixed Price delivery order is for the supply of 4565153919 HYPERRAB 300 UNIT/ML VIAL 5ML, with an ultimate completion date of August 5, 2024. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $9,391.75 Delivery Order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,860.95 delivery order contract is for the supply of HYPERRAB 300 UNIT/ML VIALML, a specialty medication. The contract is a firm fixed-price, delivery order with an ultimate completion date of April 9, 2024. No set-aside designation was used for this award. Amerisourcebergen holds a $999,999,999 Indefinite...
This federal contract award is a $1,039.53 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a completion date of February 25, 2025. The contract is not designated with a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML medical products. The $11,031.48 firm fixed price contract has a completion date of March 24, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,564.40 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, running through November 2026. This IDC serves...
This federal contract award, valued at $14,142.84, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HYPERRAB 300UNIT/ML 1S medical supplies, with a completion date of November 20, 2024. This award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,659.62 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract has a completion date of January 3, 2025 and was awarded on December 11, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FDXE3
    Delivery Order

This is a federal contract award issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $29,922.34, is a Firm Fixed Price Delivery Order for HYPERRAB 300 UNIT/ML VIAL 5ML medical supplies.

The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

Generated 5/5/25, 9:54 AM